Update from our colleagues at the Alliance for Childhood Cancer (July 13, 2020): The House Appropriations Committee agreed to fully fund the Childhood Cancer STAR
I frequently speak of viewing childhood cancer like a bicycle wheel with multiple spokes emanating from the hub in the center. Each spoke represents a
The CAC2 Survivorship Working Group assembled this document to help categorize survivorship issues for the community. It is by no means an exhaustive list, but it
Our June CAC2 All-Member webinar explored the world of clinical trials and helped us understand the important role of clinical trial navigation, a topic that is
On June 16, 2020, the Food and Drug Administration extended the indication of gemtuzumab ozogamicin (MYLOTARGTM, Wyeth Pharmaceuticals LLC) for newly-diagnosed CD33-positive acute myeloid leukemia
The American Association for Cancer Research (AACR) and the U.S. Food and Drug Administration (FDA) recorded a listening session on May 27, 2020 for patient
Our May CAC2 All-Member webinar focused on how pediatric cancer study plans are developed. CAC2 Member Kelli Wright (CureSearch) introduced Dr. Brenda Weigel from University
Day One Biopharmaceutical, a start-up biotech company founded with a focus on developing therapies for children with cancer through drug repurposing announced its debut in
Everybody is worried these days. We have witnessed toilet paper hoarding and other behaviors that make us feel vulnerable and alone. That’s why we would
Our April CAC2 All-Member webinar hosted by Donna Ludwinski (Solving Kids Cancer) introduced Drs. Jeremy Schraw and Philip Lupo of Baylor College of Medicine who spoke about
